

Thomas Reiberger

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4593079/thomas-reiberger-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268
papers

6,470
citations

41
h-index

69
g-index

349
ext. papers

9,035
ext. citations

5.5
avg, IF

6
L-index

#	Paper	IF	Citations
268	Detection of Various Microplastics in Human Stool: A Prospective Case Series. <i>Annals of Internal Medicine</i> , 2019 , 171, 453-457	8	357
267	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. <i>Hepatology</i> , 2015 , 61, 1591-602	11.2	276
266	Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Gastroenterology</i> , 2014 , 146, 1680-90.e1	13.3	257
265	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013 , 62, 1634-41	19.2	214
264	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013 , 58, 911-21	13.4	211
263	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016 , 65, 692-699	13.4	190
262	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. <i>Hepatology</i> , 2014 , 59, 1435-47	11.2	136
261	von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , 2012 , 56, 1439-47	11.2	116
260	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
259	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. <i>Scientific Reports</i> , 2018 , 8, 6220	4.9	99
258	Beta adrenergic blockade and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2017 , 66, 849-859	13.4	95
257	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015 , 35, 381-90	7.9	90
256	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018 , 154, 1694-1705.e4	13.3	90
255	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , 2017 , 66, 724-733	13.4	87
254	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. <i>Journal of Hepatology</i> , 2009 , 51, 865-73	13.4	85
253	Non-selective β blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. <i>Journal of Gastroenterology</i> , 2012 , 47, 561-8	6.9	83
252	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012 , 124, 395-402	2.3	79

251	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothIII). <i>Wiener Klinische Wochenschrift</i> , 2017 , 129, 135-158	2.3	76
250	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020 , 71, 1023-1036	11.2	67
249	The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 83-91	6.1	66
248	IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV/HCV Coinfection. <i>Antiviral Therapy</i> , 2008 , 13, 969-976	1.6	65
247	Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 139-149	6.4	63
246	An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. <i>Nature Protocols</i> , 2015 , 10, 1264-74	18.8	63
245	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1323-1333	6.1	61
244	Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. <i>Ultraschall in Der Medizin</i> , 2014 , 35, 528-33	3.8	60
243	HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 400-9	3.4	59
242	Suppression of HBV by tenofovir in HBV/HIV coinfecting patients: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2013 , 8, e68152	3.7	57
241	The profile of platelet granule released molecules affects postoperative liver regeneration. <i>Hepatology</i> , 2016 , 63, 1675-88	11.2	54
240	Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 602-8.e1	6.9	53
239	Baveno VII - Renewing consensus in portal hypertension.. <i>Journal of Hepatology</i> , 2021 ,	13.4	53
238	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015 , 35, 2121-8	7.9	52
237	Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfecting patients. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 801-10	3.4	51
236	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019 , 157, 705-719.e18	13.3	50
235	Beta blockers and cirrhosis, 2016. <i>Digestive and Liver Disease</i> , 2017 , 49, 3-10	3.3	50
234	Acid-base disorders in liver disease. <i>Journal of Hepatology</i> , 2017 , 67, 1062-1073	13.4	48

233	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015 , 277, 903-12	20.5	46
232	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 980-988	6.1	44
231	Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfecting patient. <i>Journal of Clinical Virology</i> , 2010 , 49, 131-3	14.5	43
230	Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. <i>PLoS ONE</i> , 2014 , 9, e110503	3.7	43
229	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020 , 72, 1140-1150	13.4	41
228	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 313-327.e6	6.9	41
227	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
226	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016 , 10, 424-35	8.8	40
225	Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 707-18	6.1	38
224	Metabolic preconditioning protects BSEP/ABCB11 mice against cholestatic liver injury. <i>Journal of Hepatology</i> , 2017 , 66, 95-101	13.4	37
223	Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , 2013 , 27, 227-32	3.5	37
222	Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019 , 25, 308-329	5.6	36
221	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. <i>Liver International</i> , 2015 , 35, 2115-20	7.9	36
220	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013 , 125, 200-19	2.3	36
219	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , 2019 , 25, 5897-5917	5.6	35
218	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1657-65	4	33
217	Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. <i>PLoS ONE</i> , 2012 , 7, e43143	3.7	33
216	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021 , 74, 819-828	13.4	33

215	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019 , 39, 127-135	7.9	32
214	Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. <i>Clinical Infectious Diseases</i> , 2012 , 54, 556-9	11.6	32
213	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016 , 30, 1039-47	3.5	32
212	IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. <i>Antiviral Therapy</i> , 2008 , 13, 969-76	1.6	32
211	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019 , 8, 203-217	9.1	31
210	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , 2014 , 60, 1135-42	13.4	30
209	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. <i>Hepatology</i> , 2018 , 67, 1516-1530	11.2	30
208	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015 , 35, 876-85	7.9	29
207	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. <i>Gastroenterology</i> , 2020 , 159, 534-548.e11	13.3	29
206	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020 , 73, 113-120	13.4	29
205	Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. <i>Antiviral Therapy</i> , 2011 , 16, 815-24	1.6	29
204	Low 25-OH-vitaminD levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017 , 129, 8-15	2.3	28
203	PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension. <i>PLoS ONE</i> , 2014 , 9, e108544	3.7	27
202	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018 , 130, 446-455	2.3	26
201	A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2012 , 17, 1327-34	1.6	26
200	Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. <i>PLoS ONE</i> , 2016 , 11, e0152910	3.7	26
199	Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 315, G484-G494	5.1	26
198	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 966-979	6.1	25

197	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014 , 34, 69-77	7.9	25
196	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021 , 116, 723-732	0.7	25
195	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020 , 40, 240-255	7.3	24
194	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018 , 8, 9372	4.9	24
193	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , 2019 , 39, 2374-2385	7.9	24
192	IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 599-606	4.6	23
191	Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2009 , 41, 902-6	3.3	23
190	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020 ,	1.6	23
189	Does the Functional Liver Imaging Score Derived from Gadoteric Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. <i>Radiology</i> , 2020 , 294, 98-107	20.5	23
188	Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment: Is It Worth Measuring?. <i>Current Hepatology Reports</i> , 2019 , 18, 174-186	1	22
187	Reversion and conversion of interferon- γ release assay results in HIV-1-infected individuals. <i>Journal of Infectious Diseases</i> , 2014 , 209, 729-33	7	22
186	Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 86-94	6.1	22
185	Assessment of response to beta-blockers by expression of Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , 2016 , 64, 1265-73	13.4	21
184	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018 , 38, 1036-1044	7.9	20
183	Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. <i>Visceral Medicine</i> , 2018 , 34, 270-275	2.4	20
182	Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 2340-9	3.5	20
181	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014 , 9, e95515	3.7	20
180	Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. <i>PLoS ONE</i> , 2015 , 10, e0116768	3.7	20

179	Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study. <i>Liver International</i> , 2019 , 39, 290-298	7.9	20
178	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021 , 73, 1275-1289	11.2	20
177	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015 , 10, e0143429	3.7	19
176	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021 , 70, 1758-1767	19.2	19
175	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020 , 40, 194-204	7.9	19
174	Transferrin as a predictor of survival in cirrhosis. <i>Liver Transplantation</i> , 2018 , 24, 343-351	4.5	19
173	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. <i>PLoS ONE</i> , 2018 , 13, e0189414	3.7	18
172	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1162-1169	6.1	17
171	Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment-A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2018 , 50, 1056-1061	3.3	17
170	Prognostic value of indeterminate IFN- γ release assay results in HIV-1 infection. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 2767-9	9.7	17
169	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2021 ,	13.4	17
168	Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. <i>Gut</i> , 2017 , 66, 1347-1349	19.2	16
167	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018 , 38, 1427-1436	7.9	16
166	Liver disease in adults with α -antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018 , 6, 710-718	5.3	16
165	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2021 ,	19.2	16
164	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013 , 33, 561-8	7.9	15
163	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017 , 49, 1360-1367	3.3	15
162	Molecular epidemiology of chronic hepatitis B virus infection in Greece. <i>Journal of Medical Virology</i> , 2011 , 83, 245-52	19.7	15

161	Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfecting patients. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1802-6	7	15
160	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfecting patients with advanced liver disease: A retrospective study. <i>Medicine (United States)</i> , 2016 , 95, e4061	1.8	15
159	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , 2021 , 9,	4.8	15
158	High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. <i>United European Gastroenterology Journal</i> , 2019 , 7, 507-516	5.3	14
157	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019 , 51, 1144-1151	3.3	14
156	Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	14
155	Animal models of portal hypertension. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 1019-1030	6.9	14
154	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. <i>European Journal of Clinical Investigation</i> , 2009 , 39, 65-71	4.6	14
153	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 10054-10068	3.3	14
152	When Is a Critically Ill Cirrhotic Patient Too Sick to Transplant? Development of Consensus Criteria by a Multidisciplinary Panel of 35 International Experts. <i>Transplantation</i> , 2021 , 105, 561-568	1.8	14
151	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. <i>PLoS ONE</i> , 2019 , 14, e0216677	3.7	13
150	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020 , 8, 321-331	5.3	13
149	Impact of patatin-like phospholipase domain containing 3 rs738409G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 451-459	6.1	13
148	Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. <i>European Journal of Clinical Investigation</i> , 2008 , 38, 421-9	4.6	13
147	Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?. <i>Current Hepatology Reports</i> , 2018 , 17, 301-315	1	13
146	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 184-190	4	12
145	Management of portal hypertension before and after liver transplantation. <i>Liver Transplantation</i> , 2018 , 24, 112-121	4.5	12
144	Vascular Targets for the Treatment of Portal Hypertension. <i>Seminars in Liver Disease</i> , 2019 , 39, 483-501	7.3	12

143	Revisiting predictors of virologic response to PEGIFN α 1B+RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 33-41	3.4	12
142	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013 , 27, 2707-14	3.5	12
141	Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 202, 156-60	7	12
140	PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. <i>EMBO Reports</i> , 2020 , 21, e50893	6.5	12
139	De-Ritis Ratio Improves Long-Term Risk Prediction after Acute Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	12
138	Liver Capsule: FXR agonists against liver disease. <i>Hepatology</i> , 2016 , 64, 1773	11.2	11
137	Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. <i>Infection</i> , 2016 , 44, 93-101	5.8	11
136	Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 508-16	3.4	11
135	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. <i>Investigative Radiology</i> , 2017 , 52, 462-469	10.1	11
134	The role of TIPS in the management of liver transplant candidates. <i>United European Gastroenterology Journal</i> , 2017 , 5, 1100-1107	5.3	11
133	Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. <i>PLoS ONE</i> , 2013 , 8, e66831	3.7	11
132	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
131	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2020 , 40, 2797-2807	7.9	11
130	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018 , 130, 105-114	2.3	11
129	Inter- and intra-reader agreement for gadoteric acid-enhanced MRI parameter readings in patients with chronic liver diseases. <i>European Radiology</i> , 2019 , 29, 6600-6610	8	10
128	Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. <i>PLoS ONE</i> , 2020 , 15, e0229239	3.7	10
127	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020 , 40, 1415-1426	7.9	10
126	Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. <i>AIDS Patient Care and STDs</i> , 2014 , 28, 221-7	5.8	10

125	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 309-316	2.2	10
124	The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. <i>Hepatology</i> , 2020 , 72, 584-594	11.2	10
123	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019 , 33, 197-206	5.8	9
122	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. <i>Liver International</i> , 2015 , 35, 1393-402	7.9	9
121	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 205-212	6.1	9
120	Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. <i>Gastroenterology</i> , 2018 , 154, 1550-1551	13.3	9
119	Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study. <i>Journal of Infectious Diseases</i> , 2015 , 211, 729-35	7	9
118	The risk of infections in HIV-HCV coinfecting patients during antiviral therapy with pegIFN+RBV. <i>Journal of Infection</i> , 2012 , 65, 142-9	18.9	9
117	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , 2020 , 55, 533-542	6.9	9
116	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020 , 40, 393-404	7.9	9
115	Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2019 , 9, 18541	4.9	9
114	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 2164-2172	4	8
113	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020 , 40, 1713-1724	7.9	8
112	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019 , 7, 850-858	5.3	8
111	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017 , 129, 517-526	2.3	8
110	Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , 2020 , 40, 894-904	7.9	8
109	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019 , 49, 201-211	5.1	8
108	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021 , 41, 799-809	7.9	8

107	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , 2021 , 41, 2249-2268	7.9	8
106	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
105	The influence of portal pressure on the discordance between absolute CD4+ cell count and CD4+ cell percentage in HIV/hepatitis C virus-coinfected patients. <i>Clinical Infectious Diseases</i> , 2013 , 56, 904-5	11.6	7
104	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
103	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020 , 132, 1-11	2.3	7
102	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2670-2677	5.6	7
101	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021 , 41, 2159-2170	7.9	7
100	The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality. <i>Hepatology</i> , 2021 , 74, 1533-1545	11.2	7
99	Chronic hepatitis C: treat everyone now or stratify by disease?. <i>Minerva Gastroenterologica E Dietologica</i> , 2015 , 61, 11-9	1.6	7
98	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 1008-1015	2.4	6
97	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , 2020 , 40, 787-796	7.9	6
96	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018 , 2018, 8489709	3.2	6
95	Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome. <i>PLoS ONE</i> , 2015 , 10, e0123948	3.7	6
94	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <i>Hepatology International</i> , 2020 , 14, 1083-1092	8.8	6
93	Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1174-1185	5.3	6
92	Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00326	4.2	6
91	The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016 , 36, 1649-1656	7.9	6
90	Hepatitis C Virus RNA Is Commonly Detectable in Rectal and Nasal Fluids of Patients With High Viremia. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1292-1299	11.6	6

89	Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 291-295	2.2	6
88	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018 , 44, 2578-2586	3.5	6
87	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , 2019 , 131, 395-403	2.3	5
86	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3642-3651	4	5
85	Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , 2020 , 40, 2228-2241	7.9	5
84	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , 2019 , 9, 11674	4.9	5
83	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019 , 14, e0224506	3.7	5
82	The association of smoking with IGRA and TST results in HIV-1-infected subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014 , 18, 709-16	2.1	5
81	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , 2014 , 19, 407-14	1.6	5
80	The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis.. <i>Hepatology Communications</i> , 2021 ,	6	5
79	Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2015 , 10, e0137096	3.7	5
78	Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1243-1262	6.1	5
77	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	4
76	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021 , 5, 1660-1675	6	4
75	Polyploidy control in hepatic health and disease. <i>Journal of Hepatology</i> , 2021 , 75, 1177-1191	13.4	4
74	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
73	Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. <i>Liver International</i> , 2020 , 40, 988-989	7.9	4
72	Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. <i>World Journal of Hepatology</i> , 2021 , 13, 731-746	3.4	4

71	Nuclear receptors in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021 , 1867, 166235	6.9	4
70	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , 2021 ,	5.3	4
69	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	3
68	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	3
67	Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. <i>PLoS ONE</i> , 2016 , 11, e0145319	3.7	3
66	Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2020 , 15, e0244514	3.7	3
65	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020 , 12,	6.6	3
64	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021 , 9, 427-437	5.3	3
63	Portal Hypertension after Liver Transplantation Causes and Management. <i>Current Hepatology Reports</i> , 2019 , 18, 59-66	1	3
62	Letter: sustained virological response and liver healing - authors'Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1173-1174	6.1	2
61	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019 , 7, 651-661	5.3	2
60	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	2
59	Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 452-460	2.3	2
58	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020 , 52, 1473-1479	3.3	2
57	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
56	Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. <i>PLoS ONE</i> , 2021 , 16, e0252274	3.7	2
55	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 421-431	2.3	2
54	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 335-344	5.3	2

53	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020 , 14, 1093-1103	8.8	1
52	Role of diuretics in the harmful effects of beta blockers in patients with ascites. Authors' reply. <i>Digestive and Liver Disease</i> , 2018 , 50, 102-103	3.3	1
51	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 414-20	2.3	1
50	Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis 2016 , 333-339		1
49	Reply: To PMID 24631577. <i>Gastroenterology</i> , 2014 , 147, 942	13.3	1
48	Letter: sorafenib in portal hypertension [Authors' reply]. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 994-995	6.1	1
47	Effect of liver resection-induced increases in hepatic venous pressure gradient on development of postoperative acute kidney injury.. <i>BMC Nephrology</i> , 2022 , 23, 21	2.7	1
46	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2021 ,	11.2	1
45	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2712-2718	4	1
44	PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
43	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	1
42	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , 2021 , 10, 48	1.2	1
41	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021 , 15, 1160-1173	8.8	1
40	Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach. <i>Clinics in Liver Disease</i> , 2021 , 25, 311-326	4.6	1
39	Outcomes of an HCV elimination program targeting the Viennese MSM population. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 635-640	2.3	1
38	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016 , 48, 1194-9	3.3	1
37	Letter to the Editor: Perioperative Presentation of COVID-19 in a Liver Transplant Recipient. <i>Hepatology</i> , 2021 , 73, 868-869	11.2	1
36	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021 , 16, e0256544	3.7	1

35	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
34	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2021 , 57, 99	6.9	1
33	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022 , 100513	10.3	1
32	Research update for articles published in EJCI in 2008. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 770-789	4.6	0
31	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis.. <i>Platelets</i> , 2022 , 1-8	3.6	0
30	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 1485-1493	5.3	0
29	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. <i>BMC Medicine</i> , 2020 , 18, 336	11.4	0
28	Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease. <i>PLoS ONE</i> , 2021 , 16, e0249785	3.7	0
27	Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. <i>World Journal of Gastroenterology</i> , 2021 , 27, 2281-2298	5.6	0
26	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , 2021 , 41, 2622-2634	7.9	0
25	Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.. <i>Journal of Hepatology</i> , 2022 ,	13.4	0
24	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.. <i>Advances in Medical Sciences</i> , 2022 , 67, 154-162	2.8	0
23	Reply to: "Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?". <i>Journal of Hepatology</i> , 2017 , 67, 880-881	13.4	
22	Nachbetreuung von PatientInnen mit Sustained virologic response \square <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , 2020 , 18, 110-117	0	
21	Early TIPS \square bei Varizenblutungen \square Ergebnisse aus der klinischen Routine. <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , 2018 , 16, 29-35	0	
20	Reply to: "Non selective beta blockers in cirrhosis". <i>Journal of Hepatology</i> , 2017 , 67, 1343-1344	13.4	
19	The "pegylated" story continues--perhaps because both ends (a and b) are true?. <i>Journal of Hepatology</i> , 2012 , 57, 226-8; author reply 229	13.4	
18	P2.045 Serial Testing with an Interferon-Gamma Release Assay in HIV-1-Infected Individuals. <i>Sexually Transmitted Infections</i> , 2013 , 89, A101.3-A102	2.8	

- 17 Measurement of the Hepatic Venous Pressure Gradient (HVPG) **2020**, 447-450
- 16 Liver Fibrosis and Metabolic Alterations in Adults with Homozygous Alpha1-antitrypsin Deficiency (PiZZ Genotype). *Zeitschrift Fur Gastroenterologie*, **2018**, 56, E2-E89 1.6
- 15 Secondary Prophylaxis in Special Patient Populations **2016**, 317-332
- 14 Liver fibrosis assessment and treatment initiation within a systematic screening program among HIV/HIV-coinfected patients. *Zeitschrift Fur Gastroenterologie*, **2017**, 55, e28-e56 1.6
- 13 The novel point shear-wave elastography method ElastPQ[®] is accurate for non-invasive evaluation of liver fibrosis and portal hypertension. *Zeitschrift Fur Gastroenterologie*, **2017**, 55, e28-e56 1.6
- 12 ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. *Zeitschrift Fur Gastroenterologie*, **2017**, 55, e28-e56 1.6
- 11 Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease". *Journal of Hepatology*, **2021**, 74, 1000-1001 13.4
- 10 Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease". *Journal of Hepatology*, **2021**, 75, 234-236 13.4
- 9 Author response to Letter to the Editor: MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. *Liver International*, **2021**, 41, 221-222 7.9
- 8 Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. *Digestive and Liver Disease*, **2021**, 53, 345-352 3.3
- 7 Letter to Lavian and colleagues. *European Journal of Radiology*, **2021**, 134, 109449 4.7
- 6 Author's reply to "Thromboelastometry in patients with advanced chronic liver disease: a complex interplay". *Hepatology International*, **2021**, 15, 522-524 8.8
- 5 Adequate scattergram interpretation increases the reliability of automated polymorphonuclear (pmn) cell counts from ascitic fluid of patients with liver cirrhosis. *International Journal of Laboratory Hematology*, **2021**, 43, O176-O180 2.5
- 4 Reply. *Clinical Gastroenterology and Hepatology*, **2021**, 6.9
- 3 Letter to Niezen and colleagues. *Liver International*, **2021**, 41, 2525-2526 7.9
- 2 Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.. *Journal of Hepatology*, **2022**, 13.4
- 1 Response to Letter to the Editor written by Dr. Isabelle Ollivier-Hourmand.. *Journal of Hepatology*, **2022**, 13.4